Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-based Compensation (Tables)

Stock-based Compensation (Tables)

6 Months Ended

Jun. 30, 2014

Schedule of stock-based compensation expense related to all of the entity's stock-based awards

Total stock-based compensation expense related to all of our share-based payments that we recognized for the three and six months ended June 30, 2014 and 2013 were as follows (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2014		2013		2014		2013
Research and development	$	1,189	$	1,002	$	2,503	$	2,025
General and administrative	943		745		1,993		1,515
Total stock-based compensation expense	$	2,132	$	1,747	$	4,496	$	3,540

Summary of weighted-average assumptions relating to options granted pursuant to equity incentive plans

	Equity Incentive Plans				Equity Incentive Plans
	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2014		2013		2014		2013
Risk-free interest rate	2.2	%	0.9	%	2.1	%	0.8	%
Expected term (in years)	6.7		6.0		6.5		5.5
Dividend yield	0.0	%	0.0	%	0.0	%	0.0	%
Expected volatility	76.9	%	83.8	%	75.3	%	73.9	%

Summary of weighted-average assumptions used to calculate fair value of purchase rights granted under Employee Stock Purchase Plan

	Employee Stock Purchase Plan
	Six Months Ended
	June 30,
	2014		2013
Risk-free interest rate	0.3	%	0.2	%
Expected term (in years)	1.7		1.4
Dividend yield	0.0	%	0.0	%
Expected volatility	66.0	%	58.0	%